AKT1 and Huntington disease: On day 3 following lithium-pilocarpine administration (compared with controls), the only indicated pathways were those relevant to Huntington’s disease, TNF signaling, NF-kappa B signaling, complement and coagulation cascades, MAPK signaling, PI3K-Akt signaling, apoptosis, regulation of the actin cytoskeleton, and protein processing in the endoplasmic reticulum.